Table 2

Summary of body weight development, hematology, and serum chemistry of ADAMTS13 KO mice receiving treatment with rhADAMTS13 before or after challenge with rhVWF

VariableTime point, dProphylactic treatment: 200 U/kg rhADAMTS13* + 2000 U/kg rhVWF
Therapeutic treatment: 2000 U/kg rhVWF + 320 U/kg rhADAMTS13*
After 15 min
After 30 min
After 180 min
MeannMeannMeannmeann
Body weight, Δ% 0-1 −0.7 −2.5 −3.8 −3.0 
Platelets, × 103/μL 1263 970 805 370 
Hematocrit, % 36.9 39.3 38.3 34.1 
LDH, U/L 296 256 222 206 
VariableTime point, dProphylactic treatment: 200 U/kg rhADAMTS13* + 2000 U/kg rhVWF
Therapeutic treatment: 2000 U/kg rhVWF + 320 U/kg rhADAMTS13*
After 15 min
After 30 min
After 180 min
MeannMeannMeannmeann
Body weight, Δ% 0-1 −0.7 −2.5 −3.8 −3.0 
Platelets, × 103/μL 1263 970 805 370 
Hematocrit, % 36.9 39.3 38.3 34.1 
LDH, U/L 296 256 222 206 
*

U rADAMTS13 = FRETS-U rhADAMTS13.

U rhVWF = VWF:RCoU rhVWF.

Close Modal

or Create an Account

Close Modal
Close Modal